Lantern Pharma to Host Q3 2025 Results Webcast Highlighting AI Platform Progress

Lantern Pharma (NASDAQ: LTRN), an artificial intelligence company focused on developing targeted cancer therapies, has scheduled a webcast for November 13, 2025, to discuss third-quarter operating and financial results. The event will feature President and CEO Panna Sharma alongside other management team members who will provide insights into quarterly performance, clinical trial advancements, and upcoming milestones for the company's artificial intelligence and machine learning initiatives. The webcast represents a significant opportunity for stakeholders to understand how Lantern Pharma's proprietary RADR platform is accelerating oncology drug discovery and development.

The company's AI-driven approach to cancer treatment development represents a transformative shift in pharmaceutical research methodology. Lantern Pharma's RADR platform leverages over 200 billion oncology-focused data points and utilizes more than 200 advanced machine learning algorithms to address complex challenges in cancer drug development. This technological infrastructure enables the company to potentially reduce both the cost and timeline traditionally associated with bringing new cancer therapies to market. The platform's capabilities are particularly relevant given the substantial financial investments typically required for oncology drug development and the urgent need for more effective cancer treatments worldwide.

Lantern Pharma's growing pipeline includes multiple development programs spanning various cancer indications, including both solid tumors and blood cancers, along with an antibody-drug conjugate program. The company currently maintains a Phase 2 clinical program and multiple Phase 1 clinical trials, demonstrating the practical application of its AI technology in real-world drug development scenarios. According to company information available through their newsroom at https://ibn.fm/LTRN, the combined annual market potential for Lantern Pharma's AI-driven pipeline of innovative product candidates exceeds $15 billion USD. This substantial market opportunity underscores the financial significance of the company's approach to pharmaceutical development.

The implications of Lantern Pharma's AI-driven methodology extend beyond financial considerations to potentially life-changing outcomes for cancer patients globally. By accelerating the drug discovery process and improving the precision of cancer treatments, the company's technology could provide new therapeutic options for hundreds of thousands of patients facing various cancer diagnoses. The upcoming webcast will likely address how recent developments in the company's AI platform are translating into tangible progress across its clinical programs. Investors and industry observers can access additional information about the company's announcements and updates through their official communications channels, including detailed press releases available at https://ibn.fm/BMDrb.

The convergence of artificial intelligence with pharmaceutical development represents one of the most promising frontiers in modern medicine, particularly in the complex field of oncology. Lantern Pharma's progress in this space highlights how machine learning algorithms can process vast datasets to identify patterns and relationships that might escape traditional research methods. As the company continues to advance its clinical programs and refine its AI platform, the November webcast will provide crucial insights into how these technological advancements are being operationalized to address some of the most challenging problems in cancer treatment. The integration of AI into drug development processes could potentially revolutionize how new therapies are discovered, developed, and delivered to patients in need.